Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2020
NICE publishes final guidance for Sobi's avatrombopag maleate
24 June 2020 - Avatrombopag maleate is used to treat patients with thrombocytopenia. ...
Posted by Michael Wonder on 17 Jun 2020
Final NICE green light for Janssen's Stelara in ulcerative colitis
17 June 2020 - NICE has now issued a final green light for NHS use of Janssen's Stelara (ustekinumab) to ...
Posted by Michael Wonder on 15 Jun 2020
NICE backs Rozlytrek for subset of NSCLC patients
15 June 2020 - NICE has published final draft guidance backing NHS use of Roche's Rozlytrek (entrectinib) as a treatment ...
Posted by Michael Wonder on 12 Jun 2020
NICE rejects Sanofi's Cablivi in draft guidelines
12 June 2020 - NICE has drawn up draft guidelines rejecting Sanofi's Cablivi (caplacizumab) for use alongside plasma exchange and immunosuppression ...
Posted by Michael Wonder on 11 Jun 2020
Tafamidis for treating transthyretin amyloid cardiomyopathy
11 June 2020 - The Department of Health and Social Care has asked the NICE to produce guidance on using tafamidis ...
Posted by Michael Wonder on 10 Jun 2020
Final NHS green light for Roche's Kadcyla
10 June 2020 - NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant ...
Posted by Michael Wonder on 08 Jun 2020
NICE publishes appraisal consultation for isatuximab in combination with pomalidomide and dexamethasone for treating patients with relapsed and refractory multiple myeloma
4 June 2020 - The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees ...
Posted by Michael Wonder on 04 Jun 2020
NICE publishes final guidance backing Teva's Ajovy for migraine
4 June 2020 - NICE has now published final guidelines endorsing the NHS use of Teva’s Ajovy (fremanezumab) to prevent ...
Posted by Michael Wonder on 27 May 2020
NICE issues final guidance on NHS use of Bayer's Vitrakvi
27 May 2020 - The NICE has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety ...
Posted by Michael Wonder on 27 May 2020
NICE recommends treatment for type of small-cell lung cancer
27 May 2020 - A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE. ...
Posted by Michael Wonder on 22 May 2020
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
22 May 2020 - Draft guidance published today by NICE recommends atezolizumab for treating people with a type of breast cancer, ...
Posted by Michael Wonder on 28 Apr 2020
NICE U-turn backs Stelara for ulcerative colitis
28 April 2020 - NICE has now issued a positive Final Appraisal Document recommending Janssen's Stelara (ustekinumab) as an option ...
Posted by Michael Wonder on 21 Apr 2020
Andexanet alfa for reversing anticoagulation
21 April 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using andexanet alfa ...
Posted by Michael Wonder on 21 Apr 2020
NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund
21 April 2020 - Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after ...
Posted by Michael Wonder on 16 Mar 2020
NICE hits Keytruda with ‘no’ for urothelial cancer
12 March 2020 - NICE has published a new final draft guidance recommending against the routine use of Keytruda (pembrolizumab) ...